Welcome to our dedicated page for Theriva Biologics news (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on Theriva Biologics stock.
Theriva Biologics, Inc. (NYSE American: TOVX) is a clinical-stage pharmaceutical company dedicated to developing innovative therapeutics to combat cancer and related diseases. The company's main focus is on its novel oncolytic adenovirus (OV) platform, which seeks to address devastating cancers that have high unmet medical needs.
Key Programs and Lead Candidates
- VCN-01: The company's flagship clinical-stage program, VCN-01, is designed to selectively infect and break down the tumor stroma, enhancing the efficacy of co-administered cancer therapies and promoting an anti-tumor immune response. VCN-01 has shown promising results in Phase 1 trials and is currently being evaluated in a Phase 2b trial known as VIRAGE. This trial aims to enroll up to 92 patients with metastatic pancreatic ductal adenocarcinoma (PDAC) across sites in the US and Spain.
- VCN-11: A preclinical-stage program that utilizes the company's proprietary Albumin Shield Technology to protect oncolytic viruses from the host immune system, potentially allowing for more effective systemic administration.
- SYN-004 (ribaxamase): Designed to protect the gut microbiome from the harmful effects of intravenous beta-lactam antibiotics, this therapeutic aims to prevent conditions like C. difficile infection (CDI), antibiotic-associated diarrhea (AAD), and the emergence of antimicrobial resistance (AMR).
- SYN-020: A recombinant oral formulation of intestinal alkaline phosphatase (IAP), intended to treat both local gastrointestinal and systemic diseases.
Financial and Business Updates
Theriva Biologics recently reported a 28% decrease in general and administrative expenses for the year ended December 31, 2023. This was primarily due to lower salary, investor relations, legal costs, and other expenses. Research and development expenses increased by 22% to $14.3 million, driven by higher clinical trial costs related to the VIRAGE study.
Partnerships and Achievements
Theriva Biologics collaborates with various research institutions and clinical centers across the US and Spain. The Independent Data Monitoring Committee (IDMC) recently recommended the continuation of the VIRAGE trial without any changes to the protocol, marking a significant milestone for the company's lead program.
Future Prospects
Theriva Biologics is well-positioned to advance its clinical programs and achieve several important milestones. The company expects to complete enrollment for the VIRAGE trial by the first half of 2024 and is also focusing on expanding its VCN-01 program to include combinations with other chemotherapeutic regimens.
Theriva Biologics (NYSE American: TOVX) announced its participation in the A.G.P. 2024 Virtual Healthcare Conference. The event is scheduled for May 21, 2024, at 7:30 AM ET. The company's management will provide a corporate update and participate in a fireside chat. Theriva Biologics, a clinical-stage company, focuses on developing therapeutics for cancer and related diseases. The presentation will be available via webcast.
Theriva™ Biologics, a clinical-stage company, reported positive results from a Phase 1 trial for VCN-01 in pediatric patients with retinoblastoma and presented preclinical data on VCN-01's potential in pancreatic cancer treatment. The Phase 2b trial for VCN-01 in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) is expected to complete enrollment soon. The company has $18.3 million in cash as of March 31, 2024, providing runway into Q1 2025.
FAQ
What is the current stock price of Theriva Biologics (TOVX)?
What is the market cap of Theriva Biologics (TOVX)?
What is Theriva Biologics' main focus?
What is VCN-01?
What is SYN-004 (ribaxamase)?
What recent achievements have Theriva Biologics announced?
What are the financial conditions of Theriva Biologics?
Where are Theriva Biologics' clinical trials conducted?
What future milestones does Theriva Biologics aim to achieve?
How does VCN-01 work?
What is the VIRAGE trial?
How can I get more information about Theriva Biologics?
